Your browser doesn't support javascript.
loading
The Role of the Microbiome in Gastroentero-Pancreatic Neuroendocrine Neoplasms (GEP-NENs).
Mohamed, Amr; Asa, Sylvia L; McCormick, Thomas; Al-Shakhshir, Hilmi; Dasari, Arvind; Mauricio, Retuerto; Salem, Iman; Ocuin, Lee M; Bajor, David; Lee, Richard T; Selfridge, J Eva; Kardan, Arash; Lee, Zhenghong; Avril, Norbert; Kopp, Shelby; Winter, Jordan M; Hardacre, Jeffrey M; Ammori, John B; Ghannoum, Mahmoud A.
  • Mohamed A; Division of Hematology and Medical Oncology, UH Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, USA.
  • Asa SL; Department of Pathology, UH Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA.
  • McCormick T; Department of Dermatology, Integrated Microbiome Core and Center for Medical Mycology, Case Western Reserve University, Cleveland, OH 44106, USA.
  • Al-Shakhshir H; Department of Dermatology, Integrated Microbiome Core and Center for Medical Mycology, Case Western Reserve University, Cleveland, OH 44106, USA.
  • Dasari A; Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX 77030, USA.
  • Mauricio R; Department of Dermatology, Integrated Microbiome Core and Center for Medical Mycology, Case Western Reserve University, Cleveland, OH 44106, USA.
  • Salem I; Department of Dermatology, Integrated Microbiome Core and Center for Medical Mycology, Case Western Reserve University, Cleveland, OH 44106, USA.
  • Ocuin LM; Division of Surgical Oncology, UH Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, USA.
  • Bajor D; Division of Hematology and Medical Oncology, UH Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, USA.
  • Lee RT; Division of Hematology and Medical Oncology, UH Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, USA.
  • Selfridge JE; Division of Hematology and Medical Oncology, UH Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, USA.
  • Kardan A; Department of Radiology, UH Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, USA.
  • Lee Z; Department of Radiology, UH Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, USA.
  • Avril N; Department of Radiology, UH Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, USA.
  • Kopp S; Division of Hematology and Medical Oncology, UH Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, USA.
  • Winter JM; Division of Surgical Oncology, UH Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, USA.
  • Hardacre JM; Division of Surgical Oncology, UH Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, USA.
  • Ammori JB; Division of Surgical Oncology, UH Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, USA.
  • Ghannoum MA; Department of Dermatology, Integrated Microbiome Core and Center for Medical Mycology, Case Western Reserve University, Cleveland, OH 44106, USA.
Curr Issues Mol Biol ; 44(5): 2015-2028, 2022 Apr 30.
Article en En | MEDLINE | ID: mdl-35678665
Gut microbiome balance plays a key role in human health and maintains gut barrier integrity. Dysbiosis, referring to impaired gut microbiome, is linked to a variety of diseases, including cancers, through modulation of the inflammatory process. Most studies concentrated on adenocarcinoma of different sites with very limited information on gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). In this study, we have analyzed the gut microbiome (both fungal and bacterial communities) in patients with metastatic GEP-NENs. Fecal samples were collected and compared with matched healthy control samples using logistic regression distances utilizing R package MatchIt (version 4.2.0, Daniel E. Ho, Stanford, CA, USA). We examined differences in microbiome profiles between GEP-NENs and control samples using small subunit (SSU) rRNA (16S), ITS1, ITS4 genomic regions for their ability to accurately characterize bacterial and fungal communities. We correlated the results with different behavioral and dietary habits, and tumor features including differentiation, grade, primary site, and therapeutic response. All tests are two-sided and p-values ≤ 0.05 were considered statistically significant. Gut samples of 34 patients (12 males, 22 females, median age 64 years) with metastatic GEP-NENs (22 small bowel, 10 pancreatic, 1 gall bladder, and 1 unknown primary) were analyzed. Twenty-nine patients had well differentiated GEP-neuroendocrine tumors (GEP-NETs), (G1 = 14, G2 = 12, G3 = 3) and five patients had poorly differentiated GEP-neuroendocrine carcinomas (GEP-NECs). Patients with GEP-NENs had significantly decreased bacterial species and increased fungi (notably Candida species, Ascomycota, and species belonging to saccharomycetes) compared to controls. Patients with GEP-NECs had significantly enriched populations of specific bacteria and fungi (such as Enterobacter hormaechei, Bacteroides fragilis and Trichosporon asahii) compared to those with GEP-NETs (p = 0.048, 0.0022 and 0.034, respectively). In addition, higher grade GEP-NETs were associated with significantly higher Bacteroides fragilis (p = 0.022), and Eggerthella lenta (p = 0.00018) species compared to lower grade tumors. There were substantial differences associated with dietary habits and therapeutic responses. This is the first study to analyze the role of the microbiome environment in patients with GEP-NENs. There were significant differences between GEP-NETs and GEP-NECs, supporting the role of the gut microbiome in the pathogenesis of these two distinct entities.
Palabras clave